Deadline: January 06, 2026
This initiative aims to support the pilot and implementation of cancer screening programmes for prostate cancer—offering new approaches to prevention, early detection, and national roll-out.
The focus is on evaluating the feasibility and effectiveness of implementing organised programmes based on prostate-specific antigen (PSA) testing for men, combined with additional magnetic resonance imaging (MRI) scanning as a follow-up test. The programme highlights the use of artificial intelligence (AI)-based solutions and approaches to aid the roll-out of screening programmes in Member States, provided that all such approaches remain scientifically sound and evidence-based. It builds on the groundwork laid by the Prostate cancer awareness and initiative for screening in the European Union (PRAISE-U) and preparatory actions aiming to develop European guidelines and quality assurance schemes for prostate cancer screening. There is an expectation that pilot activities and support at the national level will further promote the roll-out of organised, evidence-based screening, and enhance high standards in cancer care across the EU.
The call is open to large consortia of at least five beneficiaries from five different eligible countries. Activities include pilot studies, implementation research, extensive data collection and outcome assessment, collaboration with related projects, and the establishment of expert and stakeholder networks. The expected impact is enhanced knowledge about feasible screening modalities, increased availability and uptake of organised prostate cancer screening, and improved integration of new screening technologies—including AI—across Member States. This action aims to contribute to the overall burden reduction of communicable and non-communicable diseases, in line with the goals of Europe’s Beating Cancer Plan and the EU4Health Programme.
The estimated EU contribution for this topic is €7,440,000.
For more information, visit EC.
